Does your company provide services for stealth and startup biotechs? Check out our Sponsor Atlas: Discovering Biotech Startups series for maps on selling to these growing companies! buff.ly/2DZr2SL

Looking for more info on Biotech Showcase 2020? Check out the Racolta guide for more information! buff.ly/38nCYLO

Going to J.P. Morgan next month in San Francisco? Check out the Racolta conference guide to #JPM2020 to help make the most of your trip to the valley! buff.ly/36haHos

The latest edition of our Sponsor Atlas: Discovering Biotech Startups series is live on the Zymewire blog! In this instalment, we're looking at California's Apricity Therapeutics buff.ly/2YtYwC7

Heading to San Francisco next week for J.P. Morgan and Biotech Showcase? Don't forget to check out our conference guides for making the most of your trip to the Bay Area! blog.zymewire.com/post/biotech-s…

The first edition of Sponsor Atlas: Discovering Biotech Startups for 2020 is now live! In this installment, we're looking at Delve Therapeutics, a stealth oncology biotech out of San Francisco's MBC Biolabs accelerator. buff.ly/2tGWyTk

Sponsor Atlas: Selling to the Pharma Giants is back! It's been a while, but the new edition is looking at Chicago's AbbVie, with information about their outsourcing history, decision making, and global locations. Check it out! buff.ly/2U9o1sh

In the fight against #COVID19, we've launched COVIDCollaborators.org, an online directory of expert and discounted #drugdevelopment services being offered to researchers working on #treatments and #vaccines. Email us at [email protected] to get involved.

Thank you Atlantic Research Group for becoming #COVIDCollaborators!

The "COVID Cliff" is coming! If you sell to biotech, you're probably wondering what is happening with funding in a world changed by COVID. Join us on March 25 to explore the implications for the North American funding landscape. #CovidCliff bit.ly/3cmoRcC

Curious about what you should consider in order to build great partnerships with cell and gene therapy companies? Join industry experts and the Zymewire team for a virtual discussion on May 20 at 11 AM EST. bit.ly/3bodKQH

Join our virtual, collaborative discussion on May 20 to learn alongside Sergio Armani, Nick Stephens, and our team about how you can build strong, authentic partnerships with cell and gene therapy companies. bit.ly/3bodKQH

Join our virtual, collaborative discussion on May 20 to learn alongside Sergio Armani, Nick Stephens, and our team about how you can build strong, authentic partnerships with cell and gene therapy companies. bit.ly/3bodKQH

Everyone’s talking about remote selling these days…but what about remote buying? Listen to Scott Ballenger at Zymewire & Stefanie Guenther Kuhner at Bristol Myers Squibb discuss how you can build strong relationships that lead to lasting partnerships. youtu.be/68JBzOYYUSI

Wondering: "How the heck do I find my way around the cell & gene therapy space?" We were, too, so we worked with industry experts and used Zymewire data to build an interactive map of the sector. Check it out here bit.ly/3ioPKRA

We had all hoped for far more certainty around travel this coming fall – but it may feel like the only thing you can plan for is…more uncertainty. From recent surveys, business travel as we knew it may be a thing of the past. bit.ly/3ETprw1

One of the things I’ve missed the most is hitting the road on a sales trip, talking shop and sharing stories with my colleagues. Here's a good story: One egg or two? blog.zymewire.com/on-the-virtual…

Win or lose? It’s all about positioning. You are positioning yourself, your company, and your products every day. After a while, we get comfortable talking about our products. But in a technology-driven world, change moves quickly. bit.ly/3FkIijH

We believe getting life-saving cell and gene therapy products to patients is already complicated enough — and that figuring out where different companies fit within the sector should be the easy part. So we built a map that we hope you find useful. bit.ly/3lIPdLC

What can we learn from a hot-dog-eating champ? “The way we’ve always done things” can only lead to incremental change. It doesn’t lay the groundwork for true innovation—and it leaves us vulnerable to competitors. bit.ly/3BleJLx